Back to Annual Meeting
|
Back to Annual Meeting
|
APHA Scientific Session and Event Listing |
Winston Wong, MD, Jim Dudl, MD, and Michelle Wong, MPH, MPP. Care Management Institute, Kaiser Permanente, 1 Kaiser Plaza, Oakland, CA 94612, 510-271-4676, winston.f.wong@Kp.org
Kaiser Permanente, the nation's largest prepaid multidisciplinary health care delivery system, has launched an ambitious population management program to dramatically decrease cardiovascular morbidity and mortality among patients with diabetes and coronary artery disease. This program focuses primarily on an evidence-based and cost savings program with a pharmaceutical regimen of Aspirin, Lovastatin, and Lisinopril (ALL). Drawing upon early successes, and extending its community benefit commitment, Kaiser Permanente is embarking on implementation of the program in partnership with community-based organizations serving the medically underserved. The partnership builds upon collaboration to foster innovative care management for chronic disease. After this presentation you will be able to: *Cite the underlying population management rationale for reducing cardiovascular mortality among diabetics by implementing a three pharmaceutical regimen of aspirin, “statins”, and ACE inhibitors (ALL Program). *Identify successful implementation strategies of ALL in large, prepaid medical practices. *Describe attributes of a successful community-based model of diabetes management program targeting underserved populations. *Highlight the organizational challenges of implementing ALL in the safety net. *List critical elements for implementation of ALL in a community-based setting. *Cite positive implications of implementing ALL as a critical strategy in managing diabetic patients with limited resources.
Learning Objectives:
Keywords: Disease Management,
Presenting author's disclosure statement:
Not Answered
The 134th Annual Meeting & Exposition (November 4-8, 2006) of APHA